pGL4.75-KRAS LCS6m Citations (5)

Originally described in: KRASLCS6m
Unpublished

---

Articles Citing pGL4.75-KRAS LCS6m

Articles
The proto-oncogene KRAS is targeted by miR-200c. Kopp F, Wagner E, Roidl A. Oncotarget. 2014 Jan 15;5(1):185-95. PubMed
Novel insights into the role of microRNA in lung cancer resistance to treatment and targeted therapy. Gong Z, Yang J, Li J, Yang L, Le Y, Wang S, Lin HK. Curr Cancer Drug Targets. 2014 Mar;14(3):241-58. PubMed
Epigenetic regulation of Runx2 transcription and osteoblast differentiation by nicotinamide phosphoribosyltransferase. Ling M, Huang P, Islam S, Heruth DP, Li X, Zhang LQ, Li DY, Hu Z, Ye SQ. Cell Biosci. 2017 May 23;7:27. doi: 10.1186/s13578-017-0154-6. eCollection 2017. PubMed
miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS. Neu J, Dziunycz PJ, Dzung A, Lefort K, Falke M, Denzler R, Freiberger SN, Iotzova-Weiss G, Kuzmanov A, Levesque MP, Dotto GP, Hofbauer GFL. PLoS One. 2017 Sep 20;12(9):e0185028. doi: 10.1371/journal.pone.0185028. eCollection 2017. PubMed
MicroRNA therapeutics: design of single-stranded miR-216b mimics to target KRAS in pancreatic cancer cells. Ferino A, Miglietta G, Picco R, Vogel S, Wengel J, Xodo LE. RNA Biol. 2018;15(10):1273-1285. doi: 10.1080/15476286.2018.1526536. Epub 2018 Oct 11. PubMed

If you have published an article using this material, please email us at to have your article added to this page.